ALFA Finder| Revenue growth | 15.2% YoY for FY26; 26.4% YoY for Q4FY26. |
|---|---|
| Margins | EBITDA margin expanded from 39.2% to 43.4% YoY. |
| Demand visibility | Strong; highest ever revenue quarter in Q4FY26. |
| Management confidence | High; aiming for world-class, future-ready CRDMO platform. |
Growth
FY26 Revenue grew 15.2% YoY; EBITDA increased 30.8% and PAT surged 31.1% to ₹5,918 Mn.
Outlook
Investing ₹12,000 Mn in Unit IV greenfield expansion adding 365 KL synthesis and 100 KL fermentation capacity.
Risks
Impact from new Labour Code changes resulted in ₹244 Mn exceptional expense in FY26.
Earnings Call filed with BSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹951.15
- Market cap
- ₹53,568 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 87.2×Sector 43.8×
- Promoter holding
- 71.40%-0.02% QoQ
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Earnings Call Transcript: Key Takeaways
Anthem delivered robust Q2 results driven by CRDMO business and sharp margin expansion. Management highlighted strong operating leverage and cost discipline while scaling capacity.
- Call
- Guides 10% growth
Anthem Biosciences Investor Presentation: Key Takeaways
Q2FY27 revenue ₹5,940 Mn (+7.9% YoY), PAT ₹2,115 Mn (+21.9%), EBITDA margin 50.6% including ₹589 Mn other income. H1FY27 revenue fell 7.2%.
Anthem Biosciences Results Update
Anthem Biosciences reported Q2 FY27 consolidated revenue of ₹5,940 Mn, up 7.9% year-on-year, and PAT of ₹2,115 Mn. H1 FY27 PAT rose 7.2% to ₹3,314 Mn.
Anthem Biosciences Q2 FY27 Results: Net Profit ₹211.5 Cr, Up 22.0% YoY
Anthem Biosciences Ltd reported revenue from operations of ₹594 Cr (+7.9% YoY) and net profit of ₹211.5 Cr (+22.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹211.5 Cr · +22.0% YoY
Anthem Biosciences Board Meeting Date
Anthem Biosciences scheduled a Board meeting for November 3, 2026 to approve Q1 and H1 FY27 financial results. The trading window remains closed until November 5, 2026.
Anthem Biosciences Other Announcement
Anthem Biosciences Ltd has submitted its quarterly shareholding pattern as per SEBI regulations. The filing provides the current distribution of promoter and public shareholdings.